Arnold & Porter's Lincoln Tsang Testifies Before Congress on Effective Development of Orphan Drugs
On October 3, 2018, Arnold & Porter partner Dr. Lincoln Tsang testified before the Subcommittee on Children and Families of the US Senate Committee on Health, Education, Labor &Pensions at a hearing on 'Rare Diseases: Expediting Treatment for Patients.'
Together with patient advocates, clinicians, and other pharmaceutical industry professionals, Dr. Tsang gave an EU perspective on what the US Congress might do to improve the regulatory approval process for new transformative treatments to address the unmet needs of patients with rare genetic diseases or conditions.
It is unusual for the US Senate to invite experts from outside the US to testify, but Dr. Tsang was selected due to his longstanding expertise in the field. Prior to joining the Life Sciences practice at Arnold & Porter, he was a senior official of the Medicines and Healthcare Products Regulatory Agency and served as the UK representative on various advisory committees within the European Medicines Agency, and as an advisor to the European Commission, the Council of Europe, and the World Health Organisation.